Unique Cabozantinib Dosing Considerations in People Living with HIV and Cancer.
| Autor: | Eisenmann ED; Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio., Sparreboom A; Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Dec 15; Vol. 29 (24), pp. 4999-5001. |
| DOI: | 10.1158/1078-0432.CCR-23-2351 |
| Abstrakt: | A recent article characterized dosing recommendations for cabozantinib in people living with HIV (PLWH) and cancer, a group that is often excluded from clinical trials. This study suggests cabozantinib is effective in cancers disproportionately impacting PLWH and has translational implications for the design of studies evaluating drug-drug interactions. See related article by Haigentz et al., p. 5038. (©2023 American Association for Cancer Research.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|